Cellectis S.A.
CMVLF
Get informed when a big investor buys or sells
+ FollowMarket Cap$143.6M
Close$
Share Statistics
| Market cap | $143.60 Million |
|---|---|
| Enterprise Value | $283.52 Million |
| Dividend Yield | $NaN (NaN%) |
| Earnings per Share | $- |
| Beta | - |
| Outstanding Shares | - |
Return
| Return on Equity | -159.71% |
|---|---|
| Return on Assets | -24.53% |
| Return on Invested Capital | -37.36% |
Valuation & Multiples
| P/E Ratio | - |
|---|---|
| PEG | - |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 5.01 |
| Enterprise Value to EBIT | -5.73 |
| Enterprise Value to Net Income | -5 |
| Total Debt to Enterprise | 0.62 |
| Debt to Equity | 4.27 |
Revenue Sources
No data
Insider Trades
Institutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Cellectis
227 employees
CEO: Andre Choulika Cellectis S.A., a clinical-stage biotechnology company founded in 1999 and headquartered in Paris, France, concentrates on immuno-oncology. The firm engineers therapeutic solutions utilizing gene-edited T-cells, which are modified to dis...